IL2 and neoplasm: In parallel with the development of targeted therapy, advancements in the understanding of tumor immunology and immune evasion have driven the development of numerous drugs [18,19], with interleukin-2 (IL-2) being the first immunotherapy treatment approved for advanced or metastatic melanoma [20].